This study is accepting new patients by invitation only
Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Subjects With SCN8A-DEE
Summary
- Eligibility
- for people ages 2 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients by invitation only
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Neurocrine Biosciences
- ID
- NCT05226780
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 52 study participants
- Last Updated